{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:23:28Z","timestamp":1773275008272,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:00:00Z","timestamp":1454544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The National Science Foundation of China","award":["No.81171256"],"award-info":[{"award-number":["No.81171256"]}]},{"name":"The National Science Foundation of China","award":["No.81271487"],"award-info":[{"award-number":["No.81271487"]}]},{"name":"The National Science Foundation of China","award":["No.81270416"],"award-info":[{"award-number":["No.81270416"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11064-016-1841-0","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T05:29:21Z","timestamp":1454563761000},"page":"1375-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intranasal Delivery of Recombinant NT4-NAP\/AAV Exerts Potential Antidepressant Effect"],"prefix":"10.1007","volume":"41","author":[{"given":"Xian-Cang","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Hui","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"issue":"23","key":"1841_CR1","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095\u20133105","journal-title":"JAMA"},{"issue":"1","key":"1841_CR2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2006.07.002","volume":"113","author":"S Rosenzweig-Lipson","year":"2007","unstructured":"Rosenzweig-Lipson S et al (2007) Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113(1):134\u2013153","journal-title":"Pharmacol Ther"},{"key":"1841_CR3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.178.3.234","volume":"178","author":"ME Thase","year":"2001","unstructured":"Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234\u2013241","journal-title":"Br J Psychiatry"},{"issue":"3","key":"1841_CR4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1471-4159.1999.0721283.x","volume":"72","author":"M Bassan","year":"1999","unstructured":"Bassan M et al (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72(3):1283\u20131293","journal-title":"J Neurochem"},{"issue":"23","key":"1841_CR5","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.2174\/0929867321666140217124945","volume":"21","author":"I Magen","year":"2014","unstructured":"Magen I, Gozes I (2014) Davunetide: peptide therapeutic in neurological disorders. Curr Med Chem 21(23):2591\u20132598","journal-title":"Curr Med Chem"},{"issue":"1\u20132","key":"1841_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-8993(99)02375-6","volume":"854","author":"D Offen","year":"2000","unstructured":"Offen D et al (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson\u2019s disease. Brain Res 854(1\u20132):257\u2013262","journal-title":"Brain Res"},{"issue":"3","key":"1841_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.mcn.2010.12.011","volume":"46","author":"SM Fleming","year":"2011","unstructured":"Fleming SM et al (2011) A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 46(3):597\u2013606","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"1841_CR8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12031-012-9882-6","volume":"48","author":"Y Jouroukhin","year":"2012","unstructured":"Jouroukhin Y, Ostritsky R, Gozes I (2012) D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J Mol Neurosci 48(3):597\u2013602","journal-title":"J Mol Neurosci"},{"issue":"7","key":"1841_CR9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.peptides.2010.04.011","volume":"31","author":"A Merenlender-Wagner","year":"2010","unstructured":"Merenlender-Wagner A et al (2010) NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse\u2014a microtubule-deficient model of schizophrenia. Peptides 31(7):1368\u20131373","journal-title":"Peptides"},{"issue":"1\u20132","key":"1841_CR10","first-page":"167","volume":"19","author":"I Gozes","year":"2002","unstructured":"Gozes I et al (2002) NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 19(1\u20132):167\u2013170","journal-title":"J Mol Neurosci"},{"issue":"2","key":"1841_CR11","first-page":"16","volume":"27","author":"BH Morimoto","year":"2009","unstructured":"Morimoto BH et al (2009) Davunetide pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. Chim Oggi 27(2):16\u201320","journal-title":"Chim Oggi"},{"key":"1841_CR12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","volume":"38","author":"Y Serlin","year":"2015","unstructured":"Serlin Y et al (2015) Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol 38:2\u20136","journal-title":"Semin Cell Dev Biol"},{"key":"1841_CR13","first-page":"236","volume":"1","author":"BL Holman","year":"1972","unstructured":"Holman BL (1972) The blood brain barrier: anatomy and physiology. Prog Nucl Med 1:236\u2013248","journal-title":"Prog Nucl Med"},{"issue":"3","key":"1841_CR14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/mt.2008.283","volume":"17","author":"K Stieger","year":"2009","unstructured":"Stieger K et al (2009) Detection of intact rAAV particles up to 6\u00a0years after successful gene transfer in the retina of dogs and primates. Mol Ther 17(3):516\u2013523","journal-title":"Mol Ther"},{"issue":"5","key":"1841_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/17512433.2013.827403","volume":"6","author":"BH Morimoto","year":"2013","unstructured":"Morimoto BH et al (2013) Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol 6(5):483\u2013502","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1841_CR16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1527-3458.2005.tb00053.x","volume":"11","author":"I Gozes","year":"2005","unstructured":"Gozes I et al (2005) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11(4):353\u2013368","journal-title":"CNS Drug Rev"},{"issue":"5","key":"1841_CR17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10571-015-0165-y","volume":"35","author":"NA Vasil Yeva","year":"2015","unstructured":"Vasil Yeva NA, Murzina GB, Pivovarov AS (2015) Habituation-like decrease of acetylcholine-induced inward current in helix command neurons: role of microtubule motor proteins. Cell Mol Neurobiol 35(5):703\u2013712","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"1841_CR18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.arr.2012.08.004","volume":"12","author":"GT Wong","year":"2013","unstructured":"Wong GT, Chang RC, Law AC (2013) A breach in the scaffold: the possible role of cytoskeleton dysfunction in the pathogenesis of major depression. Ageing Res Rev 12(1):67\u201375","journal-title":"Ageing Res Rev"},{"issue":"4","key":"1841_CR19","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/mp400680d","volume":"11","author":"A Lalatsa","year":"2014","unstructured":"Lalatsa A, Schatzlein AG, Uchegbu IF (2014) Strategies to deliver peptide drugs to the brain. Mol Pharm 11(4):1081\u20131093","journal-title":"Mol Pharm"},{"issue":"6","key":"1841_CR20","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jps.20318","volume":"94","author":"CL Graff","year":"2005","unstructured":"Graff CL, Pollack GM (2005) Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 94(6):1187\u20131195","journal-title":"J Pharm Sci"},{"issue":"1","key":"1841_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","volume":"379","author":"A Mistry","year":"2009","unstructured":"Mistry A, Stolnik S, Illum L (2009) Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379(1):146\u2013157","journal-title":"Int J Pharm"},{"issue":"2","key":"1841_CR22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11095-011-0572-9","volume":"29","author":"SRK Vaka","year":"2012","unstructured":"Vaka SRK et al (2012) Delivery of brain-derived neurotrophic factor via nose-to-brain pathway. Pharm Res 29(2):441\u2013447","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"1841_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-5173(03)00039-5","volume":"255","author":"C Dufes","year":"2003","unstructured":"Dufes C et al (2003) Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255(1\u20132):87\u201397","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"1841_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijpharm.2009.05.057","volume":"378","author":"H Yu","year":"2009","unstructured":"Yu H, Kim K (2009) Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits. Int J Pharm 378(1\u20132):73\u201379","journal-title":"Int J Pharm"},{"issue":"2","key":"1841_CR25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","volume":"21","author":"D Mittal","year":"2014","unstructured":"Mittal D et al (2014) Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv 21(2):75\u201386","journal-title":"Drug Deliv"},{"issue":"2","key":"1841_CR26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/00016489.2010.518974","volume":"131","author":"G Zheng","year":"2011","unstructured":"Zheng G et al (2011) Adeno-associated viral vector-mediated expression of NT4-ADNF-9 fusion gene protects against aminoglycoside-induced auditory hair cell loss in vitro. Acta Otolaryngol 131(2):136\u2013141","journal-title":"Acta Otolaryngol"},{"issue":"4","key":"1841_CR27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0092-8674(03)00111-9","volume":"112","author":"RD Vale","year":"2003","unstructured":"Vale RD (2003) The molecular motor toolbox for intracellular transport. Cell 112(4):467\u2013480","journal-title":"Cell"},{"issue":"6","key":"1841_CR28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.npep.2013.10.011","volume":"47","author":"I Magen","year":"2013","unstructured":"Magen I, Gozes I (2013) Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides 47(6):489\u2013495","journal-title":"Neuropeptides"},{"issue":"27","key":"1841_CR29","doi-asserted-by":"crossref","first-page":"28531","DOI":"10.1074\/jbc.M403197200","volume":"279","author":"I Divinski","year":"2004","unstructured":"Divinski I, Mittelman L, Gozes I (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279(27):28531\u201328538","journal-title":"J Biol Chem"},{"key":"1841_CR30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.nbd.2013.04.012","volume":"56","author":"Y Jouroukhin","year":"2013","unstructured":"Jouroukhin Y et al (2013) NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis 56:79\u201394","journal-title":"Neurobiol Dis"},{"key":"1841_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/493670","volume":"2012","author":"A Idan-Feldman","year":"2012","unstructured":"Idan-Feldman A, Ostritsky R, Gozes I (2012) Tau and caspase 3 as targets for neuroprotection. Int J Alzheimer\u2019s Dis 2012:1\u20138","journal-title":"Int J Alzheimer\u2019s Dis"},{"issue":"10","key":"1841_CR32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/mp.2014.97","volume":"19","author":"S Oz","year":"2014","unstructured":"Oz S et al (2014) The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry 19(10):1115\u20131124","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1841_CR33","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pbb.2009.09.009","volume":"94","author":"SB Harrod","year":"2009","unstructured":"Harrod SB, Van Horn ML (2009) Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats. Pharmacol Biochem Behav 94(2):296\u2013304","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"1841_CR34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.mp.4001992","volume":"12","author":"J Mill","year":"2007","unstructured":"Mill J, Petronis A (2007) Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 12(9):799\u2013814","journal-title":"Mol Psychiatry"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1841-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-016-1841-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1841-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:39:59Z","timestamp":1559349599000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-016-1841-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s11064-016-1841-0","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}